Kahn Clare 4
4 · Solid Biosciences Inc. · Filed Jun 9, 2022
Insider Transaction Report
Form 4
Kahn Clare
Director
Transactions
- Award
Director Stock Option (Right to Buy)
2022-06-07+51,000→ 51,000 totalExercise: $0.63Exp: 2032-06-07→ Common Stock (51,000 underlying) - Award
Stock Option (Right to Buy)
2022-06-07+40,000→ 40,000 totalExercise: $0.63Exp: 2032-06-07→ Common Stock (40,000 underlying)
Footnotes (2)
- [F1]This option was granted on June 7, 2022 and vests in full on the earlier to occur of the one-year anniversary of the grant date and immediately prior to the Issuer's next annual meeting of stockholders occurring after the grant date, and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
- [F2]This option was granted on June 7, 2022 and vests in equal quarterly installments over the 12 month period following the grant date, subject to continued service as a director or consultant.